Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (ADMET) | 0 | Toxicity in human MDR1 gene transfected mouse L5178Y cells at 40 ug/ml | ChEMBL. | 18513966 |
IC50 (ADMET) | = 0.224 uM | Cytotoxicity against human RPMI8226 cells | ChEMBL. | 16996657 |
IC50 (ADMET) | = 0.229 uM | Cytotoxicity against human HCC2998 cells | ChEMBL. | 16996657 |
IC50 (ADMET) | = 0.479 uM | Cytotoxicity against human SR cells | ChEMBL. | 16996657 |
IC50 (ADMET) | = 0.562 uM | Cytotoxicity against human SW620 cells | ChEMBL. | 16996657 |
IC50 (ADMET) | = 0.776 uM | Cytotoxicity against human KM12 cells | ChEMBL. | 16996657 |
IC50 (ADMET) | = 0.884 uM | Cytotoxicity against human CEM cells | ChEMBL. | 16996657 |
IC50 (ADMET) | = 0.912 uM | Cytotoxicity against human HCT15 cells | ChEMBL. | 16996657 |
IC50 (ADMET) | = 1.02 uM | Cytotoxicity against human COLO205 cells | ChEMBL. | 16996657 |
IC50 (ADMET) | = 1.15 uM | Cytotoxicity against human NCI49 cell lines | ChEMBL. | 16996657 |
IC50 (ADMET) | = 1.32 uM | Cytotoxicity against human HL60 (TB) cells | ChEMBL. | 16996657 |
IC50 (ADMET) | = 1.38 uM | Cytotoxicity against human HCT116 cells | ChEMBL. | 16996657 |
IC50 (ADMET) | = 1.39 uM | Cytotoxicity against human Molt4/C8 cells | ChEMBL. | 16996657 |
IC50 (ADMET) | = 1.82 uM | Cytotoxicity against human K562 cells | ChEMBL. | 16996657 |
IC50 (ADMET) | = 7.14 uM | Cytotoxicity against human mouse L1210 cells | ChEMBL. | 16996657 |
LogP | = 5.5 | Lipophilicity, log P of the compound | ChEMBL. | 18513966 |
pKa | = 10.73 | Dissociation constant, pKa of the compound | ChEMBL. | 18513966 |
Ratio (binding) | = 83.7 | Reversal of P-glycoprotein-mediated multidrug resistance in human MDR1 gene transfected mouse L5178Y cells assessed as fluorescence activity ratio at 4 ug/ml by flow cytometry | ChEMBL. | 18513966 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.